

2019 Future of Pulmonary Embolism R&D Pipeline Drugs and Companies- Analysis of Global Pulmonary Embolism Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

<https://marketpublishers.com/r/2E1BA295F9AEN.html>

Date: January 2019

Pages: 40

Price: US\$ 2,199.00 (Single User License)

ID: 2E1BA295F9AEN

Abstracts

The global demand for Pulmonary Embolism treatment options is emerging rapidly driven by consumption in major emerging markets. As more growth opportunities will turn up over the medium to long term future, a large number of companies are working on Pulmonary Embolism pipeline. Companies quickly adapting to the change and moving their products to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and inadequate financial support are holding some of the Pulmonary Embolism pipeline companies from advancing their products into Phase 3 or Phase 4.

Pulmonary Embolism Report Description

The H1 2019 pipeline review report on Pulmonary Embolism pipeline is a comprehensive study on the candidates in development across different phases worldwide. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Pulmonary Embolism pipeline compounds.

The Pulmonary Embolism pipeline guide presents information on all active drugs currently being developed for Pulmonary Embolism. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Pulmonary Embolism pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Pulmonary Embolism drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Pulmonary Embolism product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Pulmonary Embolism pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Pulmonary Embolism pipeline report includes

An overview of Pulmonary Embolism disease including symptoms, causes, diagnosis and available treatment options is provided.

Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc

Phase wise count of pipeline compounds

Company wise list of pipeline compounds

Mechanism of Action wise pipeline compounds

For each pipeline product, the following details are provided-

Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)

Current status of development

Drug overview

Mechanism of Action

Pre-clinical and Clinical Trials

REASONS TO BUY

The report is designed to help industry executives promote the success and continued growth of their organizations

Get clear understanding of the entire Pulmonary Embolism pipeline, with details on active projects

Stay ahead of the competition through comprehensive knowledge of Pulmonary Embolism pipeline progress

Get in detail information of each product with updated information on each project along with key milestones

Gain clear insights into the market through in-depth strategic analysis review

Know the list of companies participating in global Pulmonary Embolism pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.

Contents

1. TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2. GLOBAL PULMONARY EMBOLISM PIPELINE OVERVIEW

- 2.1 Key Findings, 2019
- 2.2 Disease Overview
- 2.3 Report Guide and Research Methodology

3. EXECUTIVE SUMMARY

- 3.1 Pulmonary Embolism Drugs under active development, H1- 2019
- 3.2 Pipeline Drugs in Early Stage of Development (Pre-clinical, Discovery, Phase 1 and Phase 2)
- 3.3 Pipeline Drugs in Advanced Stage of Development (Phase 3, Pre-registration)
- 3.4 Companies involved in Pulmonary Embolism pipeline, H1- 2019
- 3.5 Mechanism of Action wise Pulmonary Embolism Pipeline Candidates

4. DAIICHI SANKYO CO LTD PULMONARY EMBOLISM PIPELINE DETAILS

- 4.1 Daiichi Sankyo Co Ltd Business Profile
- 4.2 Daiichi Sankyo Co Ltd Pulmonary Embolism Drug Details
 - 4.2.1 Drug Snapshot
 - 4.2.1.1 Originator
 - 4.2.1.2 Collaborator/Co-Developer
 - 4.2.1.3 Route of Administration
 - 4.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 4.2.1.5 Area
 - 4.2.1.6 Type of Molecular Entity
- 4.3 Current Status
- 4.4 Drug Overview
- 4.5 Drug Mechanism of Action
- 4.6 Clinical/Pre-clinical Trial Details
- 4.7 Latest Drug Developments

5. DONG-A SOCIO HOLDINGS PULMONARY EMBOLISM PIPELINE DETAILS

- 5.1 Dong-A Socio Holdings Business Profile
- 5.2 Dong-A Socio Holdings Pulmonary Embolism Drug Details
 - 5.2.1 Drug Snapshot
 - 5.2.1.1 Originator
 - 5.2.1.2 Collaborator/Co-Developer
 - 5.2.1.3 Route of Administration
 - 5.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 5.2.1.5 Area
 - 5.2.1.6 Type of Molecular Entity
- 5.3 Current Status
- 5.4 Drug Overview
- 5.5 Drug Mechanism of Action
- 5.6 Clinical/Pre-clinical Trial Details
- 5.7 Latest Drug Developments

6. ST PHARM CO.,LTD. PULMONARY EMBOLISM PIPELINE DETAILS

- 6.1 ST Pharm Co.,Ltd. Business Profile
- 6.2 ST Pharm Co.,Ltd. Pulmonary Embolism Drug Details
 - 6.2.1 Drug Snapshot
 - 6.2.1.1 Originator
 - 6.2.1.2 Collaborator/Co-Developer
 - 6.2.1.3 Route of Administration
 - 6.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 6.2.1.5 Area
 - 6.2.1.6 Type of Molecular Entity
- 6.3 Current Status
- 6.4 Drug Overview
- 6.5 Drug Mechanism of Action
- 6.6 Clinical/Pre-clinical Trial Details
- 6.7 Latest Drug Developments

7. TASLY PHAR. INTERNATIONAL CO., LTD PULMONARY EMBOLISM PIPELINE DETAILS

- 7.1 Tasly Phar. International Co., Ltd Business Profile
- 7.2 Tasly Phar. International Co., Ltd Pulmonary Embolism Drug Details

- 7.2.1 Drug Snapshot
 - 7.2.1.1 Originator
 - 7.2.1.2 Collaborator/Co-Developer
 - 7.2.1.3 Route of Administration
 - 7.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 7.2.1.5 Area
 - 7.2.1.6 Type of Molecular Entity
- 7.3 Current Status
- 7.4 Drug Overview
- 7.5 Drug Mechanism of Action
- 7.6 Clinical/Pre-clinical Trial Details
- 7.7 Latest Drug Developments

8. TEARX LTD. PULMONARY EMBOLISM PIPELINE DETAILS

- 8.1 TeaRx Ltd. Business Profile
- 8.2 TeaRx Ltd. Pulmonary Embolism Drug Details
 - 8.2.1 Drug Snapshot
 - 8.2.1.1 Originator
 - 8.2.1.2 Collaborator/Co-Developer
 - 8.2.1.3 Route of Administration
 - 8.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 8.2.1.5 Area
 - 8.2.1.6 Type of Molecular Entity
- 8.3 Current Status
- 8.4 Drug Overview
- 8.5 Drug Mechanism of Action
- 8.6 Clinical/Pre-clinical Trial Details
- 8.7 Latest Drug Developments

9. VERSEON CORP PULMONARY EMBOLISM PIPELINE DETAILS

- 9.1 Verseon Corp Business Profile
- 9.2 Verseon Corp Pulmonary Embolism Drug Details
 - 9.2.1 Drug Snapshot
 - 9.2.1.1 Originator
 - 9.2.1.2 Collaborator/Co-Developer
 - 9.2.1.3 Route of Administration
 - 9.2.1.4 Orphan Drug/Fast Track/Special Designation

9.2.1.5 Area

9.2.1.6 Type of Molecular Entity

9.3 Current Status

9.4 Drug Overview

9.5 Drug Mechanism of Action

9.6 Clinical/Pre-clinical Trial Details

9.7 Latest Drug Developments

10. LATEST PULMONARY EMBOLISM DRUG PIPELINE DEVELOPMENTS, 2019

11. APPENDIX

11.1 About Us

11.2 Sources and Methodology

11.3 Contact Information

I would like to order

Product name: 2019 Future of Pulmonary Embolism R&D Pipeline Drugs and Companies- Analysis of Global Pulmonary Embolism Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

Product link: <https://marketpublishers.com/r/2E1BA295F9AEN.html>

Price: US\$ 2,199.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/2E1BA295F9AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970